Advertisement

Drug Therapy: Systemic

  • Norito KatohEmail author
Chapter

Abstract

Systemic therapy is indicated for patients with severe atopic dermatitis (AD) who do not respond to adequate topical treatment or who cannot continue to receive topical therapy due to its side effects, such as skin atrophy. Before administering systemic immunosuppressive or immunomodulatory pharmaceuticals, clinicians should check whether the diagnosis of AD is correct, consider possible differential diagnoses, and examine whether the patient’s adherence to topical treatments is sufficient. The currently available immunosuppressive and immunomodulatory drugs mainly produce their anti-inflammatory effects by suppressing the proliferation and functions of lymphocytes. However, since they can cause a range of adverse effects, strict monitoring before and during treatment is mandatory. Patient education regarding the possible adverse effects of treatment, the pathogenesis of AD, and the practical measures for treating AD is very important.

Keywords

Cyclosporine Azathioprine Mycophenolic acid Methotrexate Antihistamine 

References

  1. 1.
    Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336–49. doi: 10.1016/j.jaci.2016.06.010.CrossRefPubMedGoogle Scholar
  2. 2.
    Saeki H, Nakahara T, Tanaka A, Kabashima K, Sugaya M, Murota H, Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association, et al. Clinical practice Guidelines for the Management of Atopic Dermatitis 2016. J Dermatol. 2016;43:1117–45. doi: 10.1111/1346-8138.13392.CrossRefPubMedGoogle Scholar
  3. 3.
    Tamagawa-Mineoka R, Masuda K, Ueda S, Nakamura N, Hotta E, Hattori J, et al. Contact sensitivity in patients with recalcitrant atopic dermatitis. J Dermatol. 2015;42:720–2. doi: 10.1111/1346-8138.12866.CrossRefPubMedGoogle Scholar
  4. 4.
    Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exp Dermatol. 1991;16:444–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand area = 2 FTU = 1 g. Arch Dermatol. 1992;128:1129–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Allergy. 2015;70:6–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy. 2014;69:46–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Smith GP, Chan ESL. Immunomodulating pharmaceuticals. In: Rich RR, Fleisher TA, Shearer WT, Schroeder H, Frew AJ, Weyand CM, editors. Clinical Immunology. 4th ed. Amsterdam: Elsevier; 2013. p. 1077–84.Google Scholar
  9. 9.
    Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RD, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol. 1993;129:422–30.CrossRefPubMedGoogle Scholar
  10. 10.
    van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994;130:634–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol. 1996;34:1016–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606–19.PubMedGoogle Scholar
  14. 14.
    Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol. 1995;132:106–12.CrossRefPubMedGoogle Scholar
  15. 15.
    Atakan N, Erdem C. The efficacy, tolerability and safety of a new oral formulation of Sandimmun®- Sandimmun Neoral® in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11:240–6.PubMedGoogle Scholar
  16. 16.
    Kim JE, Shin JM, Ko JY, Ro YS. Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine. Dermatol Ther. 2016;29:120–5. doi: 10.1111/dth.12333.CrossRefPubMedGoogle Scholar
  17. 17.
    Slater NA, Morrell DS. Systemic therapy of childhood atopic dermatitis. Clin Dermatol. 2015;33:289–99. doi: 10.1016/j.clindermatol.2014.12.005.CrossRefPubMedGoogle Scholar
  18. 18.
    Cookson H, Smith C. Systemic treatment of adult atopic dermatitis. Clin Med (Lond). 2012;12:172–6.CrossRefGoogle Scholar
  19. 19.
    Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68:29–35.CrossRefPubMedGoogle Scholar
  20. 20.
    Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28:689–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat. 2009;20:141–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol. 1998;11:137–40.CrossRefPubMedGoogle Scholar
  23. 23.
    Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol. 2002;43:125–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008;33:710–1.CrossRefPubMedGoogle Scholar
  25. 25.
    Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147:324–30.CrossRefPubMedGoogle Scholar
  26. 26.
    Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Murphy LA, Atherton DJ. Azathioprine as a treatment for severe atopic eczema in children with a partial thiopurine methyl transferase (TPMT) deficiency. Pediatr Dermatol. 2003;20:531–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137:870–3.PubMedGoogle Scholar
  29. 29.
    Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol. 2007;32:23–7.PubMedGoogle Scholar
  30. 30.
    Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157:127–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Hantash B, et al. Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol. 2006;142:109–10.Google Scholar
  32. 32.
    Hantash B, Fiorentino D. Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol. 2006;142:109–10.PubMedGoogle Scholar
  33. 33.
    El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172:351–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–49.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Goujon C, Bérard F, Dahel K, Guillot I, Hennino A, Nosbaum A, et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol. 2006;16:155–8.PubMedGoogle Scholar
  37. 37.
    Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24:434–9.CrossRefGoogle Scholar
  38. 38.
    Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to severe adult atopic eczema. Br J Dermatol. 2007;156:346–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Schmitt J, Schäkel K, Fölster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone versus cyclosporine for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162:661–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–9. doi: 10.1056/NEJMoa1314768.CrossRefPubMedGoogle Scholar
  41. 41.
    Jujo K, Renz H, Abe J, Gelfand EW, Leung DYM. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol. 1992;90:323–31.CrossRefPubMedGoogle Scholar
  42. 42.
    Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-γ in immune regulation: IFN-γ inhibits the proliferation of TH2 but not TH1 murine helper T lymphocyte clones. J Immunol. 1988;140:4245–52.PubMedGoogle Scholar
  43. 43.
    Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993;28:189–97.CrossRefPubMedGoogle Scholar
  44. 44.
    Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol. 2000;42:1033–40.CrossRefPubMedGoogle Scholar
  45. 45.
    Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol. 2014;41:205–12.CrossRefPubMedGoogle Scholar
  46. 46.
    Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012;26:1176–93.CrossRefPubMedGoogle Scholar
  47. 47.
    Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol. 2003;148:1212–21.CrossRefPubMedGoogle Scholar
  48. 48.
    Yamanaka K, Motomura E, Noro Y, Umeda K, Morikawa T, Umeda-Togami K, et al. Olopatadine, a non-sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis. Exp Dermatol. 2015;24:227–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808–17.CrossRefPubMedGoogle Scholar
  50. 50.
    Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol. 2010;162:217–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Church MK, Maurer M. H1-antihistamines and itch in atopic dermatitis. Exp Dermatol. 2015;24:332–3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Dermatology, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations